Valuation Lab: Cosmo valuation report “Seeing is believing” - RedHill strategic partner to sell Aemcolo in US

Friday, November 8, 2019 @ 12:30 am

Cosmo signed an exclusive US license agreement for Aemcolo with RedHill in return for a high twenty percent royalty on sales and milestones of up to USD 100 mn, while taking a 19.6% stake in RedHill. This follows Cosmo’s “equity for product” investment strategy, which reduces costs while retaining long-term value creation through its equity stake.

Key catalysts include:

Relafalk EU launch by Dr. Falk (Q4 2019)
MethyleneBlue EU launch (mid 2020)
GI Genius US approval & launch by Medtronic (end 2020)

Cosmo Valuation Report "Seeing is believing"

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

Bioversys receives USD 6 million from Guangzhou Sino-Israel Bio-Industry Investment Fund

GIBF2 to invest US$ 6m in BioVersys BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global Phase 3 registrational study
September 11, 2024

ABCDX: Heart-type fatty acid binding protein as biomarker for Transient Ischemic Attack

ABCDx, a leader in brain injury diagnostics, is proud to announce the acceptance of the article, "Heart-type fatty acid binding protein as a biomarker in transient ischemic attack," for publication in the prestigious journal, Cardiovascular Translational Research. This pivotal study highlights the innovative use of Heart-type Fatty Acid Binding Protein (H-FABP) as a diagnostic biomarker for Transi
September 9, 2024

Boehringer Ingelheim and CDR-Life advance treatment for Geographic Atrophy

Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record | ClinicalTrials.gov), an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). BI 771716 met its primary safety endpoint following intravitreal administration of single and multiple doses. Preparation for the Phase II tria
September 5, 2024

AlphaMol discovered new molecular mechanism for anti-depression drug target

The 5-HT3 receptor (5-HT3R) is a member of the Cys-loop family of ligand-gated ion channels, which are in both the peripheral and central nervous systems. 5-HT3R is involved in regulation of neurotransmitter systems implicated in the pathophysiology of major depression. In this work, AlphaMol collaborated with Max Planck Institute, discovered that different from traditional homopentamer, 5-TH3R co
September 4, 2024

leadXpro and Alipheron combine technologies for innovative early drug discovery

By applying intelligent algorithms to detect new drugs in trillions of molecules By using high-tech Cryo-EM to elucidate structures of membrane bound proteins By accelerating structure-based lead discovery to address unmet medical needs
September 3, 2024